Full Press Release Details
Lexaria Forward Stock Split
Kelowna, BC December 7, 2015 - Lexaria Corp. (LXRP-OTCQB)
(LXX-CSE) (the "Company" or "Lexaria") further to an earlier
announcement, the Company announces the earlier disclosed forward stock split of
1.1 new shares for every existing common share held, is expected to be completed
as per the following dates.
The record date is expected to be December 14, 2015, and the
Effective date for the commencement of trading on a post-split basis is expected
to be December 16, 2015; all dates subject to final regulatory approval.
There will also be a mandatory exchange, or call in , of all
paper stock certificates. Letters of transmittal will be sent to all
shareholders of record as of the Record Date requesting the share certificate
exchange. Following the deadline for mandatory exchange expected in April 2016
-all non-exchanged older certificates will no longer be accepted and will then
Electronic shareholders those shareholders who own stock in
most brokerage accounts - are not required to take any action to participate in
the forward stock split and should notice the forward adjustment and stock
symbol change on their regular account statements.
As a result of the forward stock split, a shareholder who
currently owns 1,000 shares of Lexaria will own 1,100 shares following the
Effective date, with paper certificate shareholders subject to their compliance
with the mandatory exchange deadline.
Lexaria thanks its shareholders for their continued support.
Lexaria is a food sciences company, with common shares quoted
in the USA with symbol LXRP and in Canada with symbol LXX. The company searches
for projects that could provide potential above-market returns.
To learn more about Lexaria Corp. visit www.lexariaenergy.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: the
completion and effective date of the proposed forward split. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Access to capital, or lack thereof, is a major
risk and there is no assurance that the Company will be able to raise required
working capital. Factors which could cause actual results to differ materially
from those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition, the patent application and approval process and other
factors which may be identified from time to time in the Company's public
announcements and filings. There is no assurance that the medical marijuana,
hemp oil sector, or alternative health businesses will provide any benefit to
Lexaria, or that the Company will experience any growth through participation in
these sectors. There is no assurance that existing capital is sufficient for the
Company's needs or that it will not need to attempt to raise additional capital.
There is no assurance that any planned corporate activity, business venture, or
initiative will be pursued, or if pursued, will be successful. There is no
assurance that any hemp oil or cannabinoid-based product will promote, assist,
or maintain any beneficial human health conditions whatsoever. There is no
assurance that the cannabinoid/lipid infusion technology will provide any
increase in bioavailability to any individual person. There is no assurance that
any patent application in the USA or any other nation or under any treaty will
result in the award of an actual patent; nor that an award of any actual patent
will protect against challenges from unknown third parties. There is no
assurance that any of Lexaria s postulated uses, benefits, or advantages for the
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). ViPovaTM products and Lexaria Energy products are not intended
to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.